Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- PMID: 23177514
- DOI: 10.1016/S0140-6736(12)61900-X
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Abstract
Background: No treatment options are available for patients with metastatic colorectal cancer that progresses after all approved standard therapies, but many patients maintain a good performance status and could be candidates for further therapy. An international phase 3 trial was done to assess the multikinase inhibitor regorafenib in these patients.
Methods: We did this trial at 114 centres in 16 countries. Patients with documented metastatic colorectal cancer and progression during or within 3 months after the last standard therapy were randomised (in a 2:1 ratio; by computer-generated randomisation list and interactive voice response system; preallocated block design (block size six); stratified by previous treatment with VEGF-targeting drugs, time from diagnosis of metastatic disease, and geographical region) to receive best supportive care plus oral regorafenib 160 mg or placebo once daily, for the first 3 weeks of each 4 week cycle. The primary endpoint was overall survival. The study sponsor, participants, and investigators were masked to treatment assignment. Efficacy analyses were by intention to treat. This trial is registered at ClinicalTrials.gov, number NCT01103323.
Findings: Between April 30, 2010, and March 22, 2011, 1052 patients were screened, 760 patients were randomised to receive regorafenib (n=505) or placebo (n=255), and 753 patients initiated treatment (regorafenib n=500; placebo n=253; population for safety analyses). The primary endpoint of overall survival was met at a preplanned interim analysis; data cutoff was on July 21, 2011. Median overall survival was 6·4 months in the regorafenib group versus 5·0 months in the placebo group (hazard ratio 0·77; 95% CI 0·64-0·94; one-sided p=0·0052). Treatment-related adverse events occurred in 465 (93%) patients assigned regorafenib and in 154 (61%) of those assigned placebo. The most common adverse events of grade three or higher related to regorafenib were hand-foot skin reaction (83 patients, 17%), fatigue (48, 10%), diarrhoea (36, 7%), hypertension (36, 7%), and rash or desquamation (29, 6%).
Interpretation: Regorafenib is the first small-molecule multikinase inhibitor with survival benefits in metastatic colorectal cancer which has progressed after all standard therapies. The present study provides evidence for a continuing role of targeted treatment after disease progression, with regorafenib offering a potential new line of therapy in this treatment-refractory population.
Funding: Bayer HealthCare Pharmaceuticals.
Copyright © 2013 Elsevier Ltd. All rights reserved.
Comment in
-
Evaluation of regorafenib in colorectal cancer and GIST.Lancet. 2013 Jan 26;381(9863):273-5. doi: 10.1016/S0140-6736(12)62006-6. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177516 No abstract available.
-
Regorafenib, the CORRECT way forward or just another GRIDlock?Nat Rev Clin Oncol. 2013 Jan;10(1):1. doi: 10.1038/nrclinonc.2012.222. Epub 2012 Dec 11. Nat Rev Clin Oncol. 2013. PMID: 23229184 No abstract available.
-
Gastrointestinal cancer: regorafenib, the CORRECT way forward or just another GRIDlock?Nat Rev Gastroenterol Hepatol. 2013 Jan;10(1):1. doi: 10.1038/nrgastro.2012.242. Epub 2012 Dec 11. Nat Rev Gastroenterol Hepatol. 2013. PMID: 23229325 No abstract available.
-
Regorafenib for metastatic colorectal cancer.Lancet. 2013 May 4;381(9877):1536-7. doi: 10.1016/S0140-6736(13)60975-7. Lancet. 2013. PMID: 23642693 No abstract available.
-
Regorafenib for metastatic colorectal cancer.Lancet. 2013 May 4;381(9877):1537-8. doi: 10.1016/S0140-6736(13)60977-0. Lancet. 2013. PMID: 23642695 No abstract available.
-
Regorafenib for metastatic colorectal cancer.Lancet. 2013 May 4;381(9877):1537. doi: 10.1016/S0140-6736(13)60976-9. Lancet. 2013. PMID: 23642696 No abstract available.
-
Regorafenib for metastatic colorectal cancer - Authors' reply.Lancet. 2013 May 4;381(9877):1538-9. doi: 10.1016/S0140-6736(13)60978-2. Lancet. 2013. PMID: 23642697 No abstract available.
Similar articles
-
Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: A systematic review.Cancer Treat Rev. 2018 Jan;62:61-73. doi: 10.1016/j.ctrv.2017.10.011. Epub 2017 Nov 10. Cancer Treat Rev. 2018. PMID: 29175677 Review.
-
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6. Lancet. 2017. PMID: 27932229 Clinical Trial.
-
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol. 2015 Jun;16(6):619-29. doi: 10.1016/S1470-2045(15)70156-7. Epub 2015 May 13. Lancet Oncol. 2015. PMID: 25981818 Clinical Trial.
-
Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.Ann Pharmacother. 2013 Dec;47(12):1685-96. doi: 10.1177/1060028013509792. Epub 2013 Nov 1. Ann Pharmacother. 2013. PMID: 24259629 Review.
-
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177515 Free PMC article. Clinical Trial.
Cited by
-
Regorafenib plus programmed death‑1 inhibitors vs. regorafenib monotherapy in second‑line treatment for advanced hepatocellular carcinoma: A systematic review and meta‑analysis.Oncol Lett. 2024 May 14;28(1):318. doi: 10.3892/ol.2024.14451. eCollection 2024 Jul. Oncol Lett. 2024. PMID: 38807680 Free PMC article.
-
Multimodal Treatment of Metastatic Rectal Cancer in a Young Patient: Case Report and Literature Review.Medicina (Kaunas). 2024 Apr 24;60(5):696. doi: 10.3390/medicina60050696. Medicina (Kaunas). 2024. PMID: 38792879 Free PMC article. Review.
-
Updates on the Management of Colorectal Cancer in Older Adults.Cancers (Basel). 2024 May 10;16(10):1820. doi: 10.3390/cancers16101820. Cancers (Basel). 2024. PMID: 38791899 Free PMC article. Review.
-
Therapeutic Potential of Chlorogenic Acid in Chemoresistance and Chemoprotection in Cancer Treatment.Int J Mol Sci. 2024 May 10;25(10):5189. doi: 10.3390/ijms25105189. Int J Mol Sci. 2024. PMID: 38791228 Free PMC article. Review.
-
Multikinase inhibitors modulate non-constitutive proteasome expression in colorectal cancer cells.Front Mol Biosci. 2024 May 7;11:1351641. doi: 10.3389/fmolb.2024.1351641. eCollection 2024. Front Mol Biosci. 2024. PMID: 38774235 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous